To determine the changes in the cross-sectional area (CSA) of myofibers and their subtype distribution based on the myosin isoform expression after bupivacaine (BUP) injection in the EOM of rabbits and help the understanding of strabismus correction after BUP injection in the clinical practice. A total of 32 rabbits received 0.3 mL of 1.5% BUP in the superior rectus muscle (SR) of the right eye (OD) and were sacrificed at days 7, 28, 60, and 92. Additional eight untouched rabbits were included as controls. Hematoxylin and eosin staining was performed, and ImageJ software was used to measure CSA. Immunohistochemical analysis was performed to analyze the proportion of myofibers positive for myosin types 1 (slow), 2 (fast) and embryonic. Myofiber area measurement decreased 7 days after BUP injection [SR, 1271 ± 412 μm (control) to 909 ± 255 μm (day 7)] after BUP injection, followed by an increasing trend after 28 days and normalization after 92 days [SR; 1062 ± 363 μm (day 28), 1492 ± 404 μm (day 60), 1317 ± 334 μm (day 92)]. The proportion of slow myosin-positive fibers increased in the 60-day group (88.5% ± 16.2%). There was no statistically significant difference in fast myosin-positive fibers. The inferior rectus of both eyes showed an increase in CSA. No increase of endomysial fibrous tissue was observed after 60 and 92 days of BUP injection. Bupivacaine, when injected into the SR of rabbits, initially decreases the fiber area followed by a transient increasing trend and normalization. There is a transient increase in the proportion of slow myosin-positive fibers in the injected muscle. Muscle adaptation in untreated EOM was found with increased CSA. These findings help clarify the clinical effects of BUP in extraocular muscle.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.exer.2018.03.004 | DOI Listing |
Addict Sci Clin Pract
December 2024
Department of Medicine, Addiction Medicine Section, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239-3098, USA.
Clin Drug Investig
December 2024
Research and Development, Indivior Inc., North Chesterfield, VA, USA.
Background And Objectives: Buprenorphine extended-release monthly formulation (BUP-XR, SUBLOCADE) is approved for treatment of moderate-to-severe opioid use disorder (OUD) following subcutaneous injection in the abdomen. This open-label pharmacokinetic study assessed three alternative injection locations (upper arm, thigh, buttocks) to offer additional flexibility considering the chronic nature of the disease and patient preferences.
Methods: Following stabilization on 12/3 mg/day of sublingual buprenorphine/naloxone for ≥ 7 days, participants with moderate-to-severe OUD were randomized to receive a single 300-mg BUP-XR injection in the upper arm, thigh, buttocks, or abdomen (reference).
Immunopharmacol Immunotoxicol
December 2024
Department of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, Egypt.
Background: The aim of the current study is to identify the possible protective effect of bupropion (BUP) on liver injury in rat model of myocardial infarction (MI). BUP was administered in the presence and absence of MI.
Materials And Methods: Thirty-two Wistar adult male rats were randomly arranged into four groups: control, BUP (30 mg/kg/day, intraperitoneal) for 28 days, isoproterenol (ISO) was injected subcutaneous (85 mg/kg) in the 26th and 27th days and BUP/ISO groups.
Drug Alcohol Rev
October 2024
National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Drug Alcohol Depend
November 2024
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada; ICES, Toronto, Canada; Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!